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Lysobactor enzymogenes strain OH11 is an emerging biological control agent of fungal and bacterial diseases. We
recently completed its genome sequence and found it contains a large number of gene clusters putatively responsible
for the biosynthesis of nonribosomal peptides and polyketides, including the previously identified antifungal
dihydromaltophilin (HSAF). One of the gene clusters contains two huge open reading frames, together encoding 12
modules of nonribosomal peptide synthetases (NRPS). Gene disruption of one of the NRPS led to the disappearance
of a metabolite produced in the wild type and the elimination of its antibacterial activity. The metabolite and
antibacterial activity were also affected by the disruption of some of the flanking genes. We subsequently isolated
this metabolite and subjected it to spectroscopic analysis. The mass spectrometry and nuclear magnetic resonance
data showed that its chemical structure is identical to WAP-8294A2, a cyclic lipodepsipeptide with potent anti-
methicillin-resistant Staphylococcus aureus (MRSA) activity and currently in phase I/II clinical trials. The WAP-
8294A2 biosynthetic genes had not been described previously. So far, the Gram-positive Streptomyces have been the
primary source of anti-infectives. Lysobacter are Gram-negative soil/water bacteria that are genetically amendable
and have not been well exploited. The WAP-8294A2 synthetase represents one of the largest NRPS complexes,
consisting of 45 functional domains. The identification of these genes sets the foundation for the study of the
WAP-8294A2 biosynthetic mechanism and opens the door for producing new anti-MRSA antibiotics through
biosynthetic engineering in this new source of Lysobacter.
The discovery of new anti-infectives is a pressing and con-
tinual need for human health due to the constant emergence of
drug-resistant pathogens (50, 51). Natural products (NPs) have
been a very prolific source of anti-infective agents. Tradition-
ally, soil bacteria, especially the Gram-positive Streptomyces,
have been the primary source for anti-infectives. However,
many “user-friendly,” prolific NP producers, such as the Gram-
negative soil/water bacteria Lysobacter spp., have not been well
explored.
Lysobacter belongs to the Xanthomonadaceae family within
the Gammaproteobacteria (10, 48). They are ubiquitous inhab-
itants of soil and water. These Gram-negative gliding bacteria
have drawn increased attention for their ecological diversity,
industrial applications and, most notably, unique biotic inter-
actions. Lysobacter species display a number of unique traits
that distinguish them from other taxonomically and ecologi-
cally related microbes (10, 48). These include a high-GC ge-
nome (65 to 72%), gliding motility but without flagella, and
prolific production of extracellular lytic enzymes. Within the
genus, Lysobacter enzymogenes is the best-known species (54).
We have been using L. enzymogenes strains C3 and OH11 as
new sources for bioactive NP discovery and as new biocontrol
agents of crop diseases (29–31, 33, 39, 52). Strain C3 was
originally isolated from grass foliage and exhibits field efficacy
against a wide range of fungal pathogens (14, 25, 26, 53, 55,
57). Strain OH11 was isolated from the rhizosphere soil of
pepper plants (39). Both strains are emerging as novel agricul-
tural biocontrol agents with a broad spectrum of antifungal and
antibacterial activities.
Producing bioactive small-molecule NPs is a characteristic of
the biocontrol strains. Shown in Fig. 1 are examples of NPs
isolated from various Lysobacter species. Lysobactin (katanosin
B) was isolated from Lysobacter sp. SC14067 (7, 20, 37); tripro-
peptins were isolated from Lysobacter sp. BMK-333-48F3 (18,
19). Both lysobactin and tripropeptins are cyclic peptides
with strong anti-methicillin-resistant Staphylococcus aureus
(MRSA) and anti-vancomycin-resistant Enterococcus (VRE)
activities. Cephabacins have been isolated from Lysobacter
lactamgenus (17, 36, 45). These compounds belong to the
cephem-type -lactams, composed of a cephem nucleus, an
acetate unit, and an oligopeptide side chain. Dihydromaltophi-
lin (HSAF) was isolated from Streptomyces sp. (15) and L.
enzymogenes (29–31, 33, 52). This compound belongs to poly-
cyclic tetramate macrolactams, which are emerging as a new
class of NPs with distinct structures and a new mode of action
(6, 8). Dihydromaltophilin exhibits potent inhibitory activities
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against a wide range of fungi and shows a novel mode of action,
as it disrupts the biosynthesis of sphingolipids (30). WAP-
8294As are cyclic depsipeptides originally isolated from Lyso-
bacter staphylocidin (16, 22–24). They are potent anti-MRSA
compounds (50% effetive dose [ED50]14 times more active
than vancomycin) and, among them, WAP-8294A2 is in phase
I/II clinical studies by aRigen Pharmaceuticals (1). However,
the WAP-8294A2 biosynthetic genes have not been described
previously, and the molecular mechanism by which Lysobacter
synthesizes WAP-8294A2 remains unclear.
We obtained the genome sequence of L. enzymogenes OH11.
The genome contains a large number of genes that are pre-
dicted for NP biosynthesis. Among them, at least nine clusters
contain polyketide synthase and nonribosomal peptide synthe-
tase (PKS-NRPS) genes, including the HSAF cluster (33, 52).
The products of the remaining clusters are not clear. Here, we
report the identification and characterization of the WAP-
8294A2 biosynthetic gene cluster from L. enzymogenes OH11.
MATERIALS AND METHODS
Bacterial strains, plasmids, and general DNA manipulations. Escherichia coli
DH5 strain was used as the host for general DNA propagation. E. coli S17-1
was used as the conjugal strain. L. enzymogenes and other bacterial strains were
grown in Luria-Bertani (LB) broth medium or 1/10-strength tryptic soy broth
(TSB; Sigma). Genomic DNA of L. enzymogenes was prepared as previously
described (25). The pGEM-zf series from Promega (Madison, WI) and
pANT841 (41) were used for cloning and sequencing. Plasmid preparation and
DNA gel extraction were carried out using kits from Qiagen. PCR primers were
synthesized by Integrated DNA Technologies (Coralville, IA). All other manip-
ulations were performed according to standard methods (44).
Generation of gene disruption mutants. To construct the plasmid vectors for
gene disruption, an internal fragment was amplified from each of the open
reading frames (ORFs) by using the primer pairs described in the supplemental
material. Genomic DNA from the wild-type L. enzymogenes OH11 served as the
FIG. 1. Chemical structures of representative bioactive natural products isolated from various species of Lysobacter.
5582 ZHANG ET AL. ANTIMICROB. AGENTS CHEMOTHER.
PCR template. Primers waps1-F and waps1-R were used to amplify a 442-bp
fragment from WAPS1 (ORF3, encoding the 7-module NRPS). The fragment
was digested with XhoI/BamHI and then cloned into the conjugation vector
pJQ200SK (40) to produce pJQ200SK-waps1. Primers orf4-F and orf4-R were
used to amplify a 437-bp fragment from ORF4 (taurine catabolism dioxygenase).
Primers orf8-F and orf8-R were used to amplify a 575-bp fragment from ORF8
(TonB-dependent receptor). Both fragments were digested with BamHI/XbaI
and then cloned into the conjugation vector pJQ200SK to produce pJQ200SK-
orf4 and pJQ200SK-orf8, respectively. Each of the pJQ200SK constructs was
transformed into E. coli S17-1, which was mated with L. enzymogenes OH11 for
conjugal transfer of the vectors. The positive colonies grown on LB plates
containing gentamicin (20 g/ml) were picked and inoculated into liquid cultures
containing gentamicin. Genomic DNA was prepared from each of the cultures,
and diagnostic PCR was performed to identify mutants that resulted from a
homologous recombination. To screen the WAPS1 gene disruption mutants,
PCR was performed using the primers waps1-V-F and pJQ-R, which amplified a
584-bp fragment when mutants resulted from a homologous recombination, but
not from the wild type or mutants that resulted from a random insertion of the
construct (see Fig. S1A in the supplemental material). To screen the ORF4 gene
disruption mutants, PCR was performed using the primers orf4-V-F and pJQ-R,
which amplified an 826-bp fragment when mutants resulted from a homologous
recombination (see Fig. S1B). To screen the ORF8 mutants, primers orf8-V-F
and pJQ-R were used to amplify a 1,074-bp fragment from homologous recom-
bination mutants (see Fig. S1C). Because the signal was weak, the mutants were
further checked using primers orf8-F and pJQ-R to amplify the 654-bp product
(see Fig. S1C).
Production and analysis of the metabolites in mutants. OH11 or its mutant
was grown in 1/10 TSB for 1 day, and an aliquot of 2 ml was transferred to a
250-ml flask containing 50 ml of fermentation medium (2.5% glucose, 2% soy-
bean flour, 0.4% soybean oil, 0.25% NaCl, 0.5% CaCO3; pH 7.2). The culture
was incubated at 28°C for 3 days with shaking at 200 rpm. To extract the
metabolites, the 50-ml broth culture was collected, and the pH was adjusted to
2.5 with 1 N HCl. The supernatant was extracted with n-butanol–ethyl acetate
(1/1, vol/vol) containing 0.05% trifluoroacetic acid (TFA). The organic phase was
dried with a rotavapor (R-200; Buchi) to obtain the crude extract. The extract
was dissolved in 2 ml methanol containing 0.05% TFA. A 50-l aliquot of each
extract was analyzed by high-pressure liquid chromatography (HPLC; ProStar
210; Varian) using a reverse-phase column (Alltima C18LL; 5 m; 4.6 mm by 250
mm). Water–0.025% TFA (solvent A) and acetonitrile–0.025% TFA (solvent B)
were used as the mobile phases with a flow rate of 1.0 ml/min. The HPLC
program was as follows: 5 to 25% solvent B in solvent A for the first 0 to 10 min,
with an increase to 80% B at 25 min, to 100% at 26 min, and back to 5% B at
30 min. The metabolites were detected at 220 nm on a UV detector (ProStar 310;
Varian).
Antibacterial activity test. Bacillus subtilis was used as the indicator strain for
anti-Gram-positive bacterial activity of various strains of Lysobacter. B. subtilis
was mixed with LB medium (20 ml) and poured into a plate. After solidification
of the agar plate, sterilized stainless steel tubes were put on the surface of the LB
plate, and aliquots (50 l) of various Lysobacter extracts were added into each of
the tubes. The plates were incubated at 37°C overnight until clear inhibition
zones appeared.
Preparation of WAP-8294A2 and MS and NMR analysis. To prepare WAP-
8294A2, the fermentation broth (8 liters) was centrifuged, and the cell mass was
discarded. The supernatant was collected, evaporated in vacuo to 1 liter, and
partitioned with ethyl acetate (EtOAc) until the EtOAc layer was colorless. The
aqueous phase was partitioned with n-butanol as TFA was added to the solvent
system at 0.005 M. The n-butanol layer was concentrated, and a crude extract was
precipitated by addition of acetone. The precipitate was collected through fil-
tration and dissolved in methanol (MeOH) to obtain MeOH extract (15 g). The
MeOH extract (15 g) was divided into two parts and subjected to medium-
pressure LC (MPLC; 80 g RP-18 silica gel; 60% and 100% MeOH containing
0.005 M TFA; 800 ml for each gradient) to obtain two fractions (a and b).
Fraction a (440 mg) was separated by column chromatography (CC) on Sepha-
dex LH-20 (in MeOH containing 0.005 M TFA) to obtain fraction a1 (58.3 mg).
Fraction b (1.5 g) was subjected to CC on Sephadex LH-20 (in MeOH containing
0.005 M TFA) and further fractionated on MPLC (30 g RP-18 silica gel; 60% and
100% MeOH containing 0.005 M TFA; 300 ml for each gradient) to afford
fraction b1. Fraction a1 and fraction b1 were combined and applied to CC (100
g macroporous resin D101; 70%, 100% MeOH, and 100% MeOH containing
0.005 M TFA) to obtain fraction ab1. Fraction ab1 (32.6 mg) was further purified
on a semipreparative HPLC column of ZORBAX Eclipse XDB-C18 (9.4 by 250
nm; Agilent). The mobile phases were water (phase A) and MeOH (phase B)
containing 0.005 M TFA, respectively, with a gradient of 70% mobile phase B in
mobile phase A in the first 3 min, 70% to 85% mobile B in mobile A from 3 to
16 min, 85% to 70% mobile B in mobile A from 16 to 17 min, and 70% mobile
B in mobile A from 17 to 20 min. The flow rate was 4 ml/min. The peaks were
detected at 280 nm on a UV-visible detector. The peak with a retention time of
12 min was collected and dried to obtain WAP-8294A2 (6 mg). To analyze the
structure of the compound, high-resolution quadrupole time of flight mass spec-
trometry (HR-Q-TOF-MS) data were acquired by using Agilent Q-TOF 6520
mass spectrometer. Nuclear magnetic resonance (NMR) spectra (1H and 13C
NMR and heteronuclear single quantum correlation [HSQC]) were recorded on
a Bruker DRX-600 spectrometer, at 600/150 MHz, respectively, in DMSO-d6, 
in ppm relative to Me4Si.
RESULTS
The 12-module NRPS genes. We initially found a strong
antifungal activity in L. enzymogenes and subsequently identi-
fied the antifungal dihydromaltophilin (HSAF) and its biosyn-
thetic genes (33, 52). During this process, we noticed that
strain OH11 also has a potent activity against bacteria. To
determine the component(s) responsible for this antibacterial
activity, we first analyzed the recently completed genome draft
(5.6 Mb, putatively for 4,043 genes, with a GC content of
70.03%) of L. enzymogenes OH11. Our focus was on large gene
clusters in the genome that presumably are dedicated to
complex natural product (NP) biosynthesis. This revealed at
least nine gene clusters, including those for multimodular
polyketide synthase (PKS) and nonribosomal peptide synthe-
tase (NRPS). Among them, a cluster (designated WAPS; ac-
cession number JN596952) appeared particularly interesting
because it hosts two huge NRPSs that are next to each other.
One NRPS (WAPS1) contains 7 modules, and the other
(WAPS2) contains 5 modules (Fig. 2). Together, there are a
total of 45 domains that make up the 12 NRPS modules, which
represent one of the largest NRPS complexes. The complex is
rich in epimerase (E) domains, implying that its product(s) is
rich in D-amino acids. Additionally, the cluster hosts genes
predicted to encode enzymes putatively involved in tailoring,
resistance, and regulation (Fig. 2).
Antibacterial activity and metabolites in NRPS disruption
mutants. To find out the product(s) synthesized by this large
NRPS cluster, we first disrupted ORF3, which encodes the
7-module WAPS1. The first adenylation domain of this NRPS
was specifically disrupted by homologous recombination. The
resulting mutants (M3-6 and M3-8 are shown) did not have any
obvious differences from the wild type except for the loss of the
inhibitory activity against B. subtilis (Fig. 3). This suggests that
the WAPS cluster is likely to be a major contributor, if not the
only one, to the activity against Gram-positive bacteria. We
then set out to identify the compound(s) that is responsible for
this activity. The total metabolites from six independent mu-
tant strains were compared to that from the wild type by
HPLC. All strains showed the absence of a major peak (reten-
tion time, 23.27 min), as well as a few minor peaks, compared
to the metabolite profile of the wild type (Fig. 3). We then
purified this major metabolite and found that it indeed had
anti-Bacillus activity.
Chemical structure of the main active compound. We pre-
pared 6 mg of the compound from 8 liters of OH11 culture.
The compound was isolated as a white powder. HR-electros-
pray ionization (ESI)-MS gave an m/z of 1,562.8255 for
[M(C73H111N17O21)  H]
 (calculated, 1,562.8219). Its 1H
and 13C NMR data are summarized in Table 1 (1H and 13C
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NMR spectra and selected HSQC correlations are provided in
the supplemental material). A comparison of these data to
those in the literature readily revealed that this compound is
WAP-8294A2, a cyclic lipodepsipeptide originally isolated
from L. staphylocidin (16, 22–24). WAP-8294A2 consists of 12
amino acid residues and a fatty acid side chain (3-hydroxy-7-
methyloctanoic acid) (Fig. 1). The amino group of the first
amino acid (L-Ser1) is capped with the fatty acid side chain by
forming an amide bond with the carboxyl group of the fatty
acid. The carboxyl group of the last amino acid (N-Me-Val12)
is condensed with the 3-hydroxy group of the fatty acid side
chain to form the only ester bond of the cyclic depsipeptide. Six
of the 12 amino acids are in a D-configuration, the -amino
nitrogens of three amino acids are methylated, and both Asn2
and the fatty acid side chain contain a -hydroxyl group. The
results demonstrated that the WAPS cluster is responsible for
the biosynthesis of WAP-8294A2. Since the disruption of the
WASP1 gene also led to the disappearance of at least one
other compound with similar retention time as WAP-8294A2,
it is likely that this gene cluster is also responsible for other
members in the WAP-8294A family that differ only in the acyl
side chain length (Fig. 1) (16, 22–24).
Predicted substrate specificity of NRPS adenylation domains.
The substrate specificity of the adenylation (A) domains of the 12
NRPS modules were predicted based on sequence alignments
of the 10-amino-acid “nonribosomal peptide codes” defined by
FIG. 2. Map of the 63,187-bp WAPS gene cluster from L. enzymogenes OH11. This gene cluster contains two giant NRPSs (WAPS2 and
WAPS1), made up of a total of 12 modules. The domain compositions of the NRPSs are indicated. Abbreviations: A, adenylation domain, C,
condensation domain; E, epimerase domain; T, thiolation (PCP) domain; TE, thioesterase domain; MT, methyltransferase domain.
FIG. 3. HPLC analysis and antibacterial activity test of the gene disruption strains. M8, mutant of ORF8; M4, mutant of ORF4; M3, mutant
of ORF3; WT, wild type. The arrows indicate WAP-8294A2 or a putative analog. In the activity test, Bacillus subtilis was used as the testing
organism, and two independent strains of each of the mutants were tested.
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Stachelhaus et al. (42, 46). Table S1 in the supplemental ma-
terial shows the predicted “nonribosomal peptide codes” from
the A domains of the 7-module WAPS1, which would activate
and incorporate Ser1, Asn2, Ser3, Gly4, Phe5, Leu6, and Orn7,
and of the 5-module WAPS2, which would activate and incor-
porate Glu8, Asn9, Trp10, Orn11, and Val12. The results were in
good agreement with the amino acid sequence in the chemical
structure of WAP-8492A2, suggesting a colinear assembly line
of the modular template for peptide biosynthesis (34).
The WAPS gene cluster. Having identified the product of the
WAPS gene, we then tried to define the gene cluster required
for WAP-8294A2 biosynthesis. Immediately upstream of the
5-module WAPS2 is an MbtH-like protein (ORF1). This is a
small protein known to be associated with certain NRPS and
required for biosynthesis (13, 56). Interestingly, there is no
apparent ORF in the 4.3-kb upstream region of ORF1. The
further upstream region contains ORFs predicted to encode a
putative DNA mismatch repair protein, endonuclease subunit,
and other products that do not appear to be relevant to WAP-
8294A2 biosynthesis. Downstream of the 7-module WAPS1
are a series of tightly clustered ORFs (Fig. 2). ORF4 is ho-
mologous to taurine catabolism dioxygenase, which is a non-
heme iron, 2-ketoglutarate-dependent oxygenase (49). We
subsequently disrupted this gene and found that the mutants
TABLE 1. 1H and 13C NMR spectroscopic data for WAP-8294A2 measured in DMSO-d6 at 600 and 150 MHz, respectively
Structural moiety Position(s) H (ppm) C (ppm) Structural moiety Position(s) H (ppm) C (ppm)
3-OH-7-Me-octanoic acid CO 169.3 C- 1.66 30.2
C-2 2.31, 2.56 38.1 C- 1.55 22.9
C-3 4.92 70.9 C- 2.84 38.4
C-4 1.50 33.0 NH2 7.77
C-5 1.22 21.9 NH 7.49
C-6 1.12 38.0
C-7 1.48 27.2 Glu CO 169.8
C-8, C-8 0.82 22.2, 22.3 C- 4.61 51.2
C- 1.66, 1.80 28.5
Ser1 CO 169.5 C- 2.18 29.6
C- 4.85 53.8 CO- 174.0
C- 3.47, 3.54 62.8 NH 8.55
NH 7.96
Asn CO 170.4
OHAsn CO 169.1 C- 4.78 49.1
C- 4.98 54.5 C- 2.42, 2.61 38.0
C- 4.24 71.2 C- 171.8
CO- 173.5 NH- 6.95
NH- 7.38 NH- 7.35
NH- 7.44 NH 8.21
NH 8.10
Trp CO 170.6
Ser2 CO 169.8 C- 4.72 52.6
C- 4.85 54.7 C- 2.78, 3.12 27.3
C- 3.62 62.0 C-2 7.14 123.2
NH 8.34 C-3 109.2
C-4 7.46 118.0
Gly CO 169.0 C-5 6.87 117.9
C- 3.87 42.1 C-6 6.98 120.6
NH 8.23 C-7 7.31 111.3
C-8 127.1
NMePhe CO 169.4 C-9 135.7
C- 4.42 63.5 NH-1 10.27
C- 2.94, 3.26 33.8 NH 8.80
C-1 138.2
C-2, C-6 7.16 129.0 Orn2 CO 170.1
C-3, C-5 7.27 128.3 C 4.56 48.2
C-4 7.21 126.3 C 1.55, 1.66 28.0
N-Me 2.58 35.3 C 1.46 23.1
C 2.78 38.6
Leu CO 171.5 NH2 7.77
C- 4.24 51.2 NH 8.00
C- 1.36, 1.52 39.2a
C- 1.38 24.0 NMeVal CO 169.0
C- 0.65 20.7 C- 4.60 60.8
C- 0.69 22.8 C- 2.06 25.4
NH 7.96 C- 0.69 17.9
C- 0.86 19.0
Orn1 CO 170.9 N-Me 2.52 29.0
C- 4.65 50.6
a Overlapped with the carbon signal of dimethyl sulfoxide (DMSO)-d6 and was recognized by assignment of HSQC correlations.
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lost antibacterial activity as well as the WAP-8294A2 peak on
HPLC (Fig. 3). The result showed that ORF4 is essential for
WAP-8294A2 biosynthesis. WAP-8294A2 contains two hy-
droxyl groups, one on -hydroxy Asn2 and the other on 3-hy-
droxy fatty acyl chain. This dioxygenase is likely involved in one
or both of the hydroxylations. ORF5 is homologous to efflux
transporters. The ORF5 disruption mutant still exhibited the
antibacterial activity and produced WAP-8294A2 (data not
shown). ORF6 is homologous to pectin lyase fold/virulence
factor, which is related to peptidases. The disruption of this
gene led to the loss of antibacterial activity and the disappear-
ance of the WAP-8294A2 peak on HPLC (data not shown).
ORF7 is homologous to lytic endopeptidase preproenzyme,
which is related to a family of bacterial extracellular metalloen-
dopeptidases. ORF5, -6, and -7 may be involved in self-pro-
tection. ORF8 is homologous to the TonB-dependent recep-
tor, part of a family of outer membrane -barrel proteins that
sense extracellular signals (35). The disruption of this gene led
to a partial loss of the antibacterial activity and a reduced
WAP-8294A2 peak on HPLC (Fig. 3). The result suggests that
ORF8 is involved but not essential for WAP-8294A2 produc-
tion, consisting with the predicted function of this gene as a
regulator. Interestingly, the WAP-8294A2 peak was signifi-
cantly smaller than that in the wild type, while the antibacterial
activity was only partly reduced. One possibility is that the
inactivation of this receptor gene could have led to activation
of biosynthesis of other antibacterial metabolites, as evidenced
by HPLC with multiple new peaks that resulted from this
mutation. ORF9 is homologous to SapC-related protein, which
is related to peptide transport (38), and ORF10 is homologous
to Pass1-related protein (32). These two ORFs and ORF5 may
be involved in WAP-8294A transport. It is notable that the
WAPS gene cluster contains an unusually high number of
resistance and transport-related genes. The downstream re-
gion of ORF10 contains ORFs homologous to cellulase, glu-
cokinase, and other sugar-related products, which do not ap-
pear to be relevant to WAP-8294A biosynthesis. Together, the
data suggest that the region between ORF1 and ORF10 is the
WAPS gene cluster.
All WAP-8294A compounds contain a 3-hydroxy fatty acyl
chain. However, there is not a candidate for acyl coenzyme A
(CoA) ligase (ACL) present in this gene cluster or its flanking
regions. Such an enzyme is needed to activate and introduce
the 3-hydroxy fatty acid chain into the peptide. The activated
acyl-S-CoA can directly serve as substrate to be incorporated
into the peptide (21) or is transferred to a dedicated acyl
carrier protein (ACP) as acyl-S-ACP, which is then incorpo-
rated into the peptide (4). To test if the WAP assembly could
use an ACL in other metabolic pathways, we disrupted an
ACL-encoding ORF (accession number JN596953) present in
one of the uncharacterized PKS/NRPS gene clusters found in
the genome of OH11. The mutants showed a partial loss of
the antibacterial activity and produced approximately 50%
of the WAP-8492A yield of the wild type (data not shown). The
results suggested that the WAP-8492A biosynthetic pathway
likely recruits an ACL from other pathways. This type of in
trans ACL generally exhibits a broad specificity and is func-
tionally redundant (2), which is consistent with the fact that all
WAP-8492A compounds have the same amino acid composi-
tion but vary in the length of the fatty acid side chain (16,
22–24).
DISCUSSION
A huge number of gene clusters discovered by genome se-
quencing have been predicted for secondary metabolite bio-
synthesis in numerous microbes. In many cases, the actual
products of the gene clusters remain unclear. In this work, we
identified the product of a previously uncharacterized NRPS
gene cluster from the recently completed genome sequence of
the biocontrol agent L. enzymogenes OH11. This strain exhib-
ited a strong antibacterial activity, but the active component(s)
for this activity was not known. Through genome mining, tar-
get-specific gene disruption, metabolite isolation, and struc-
tural elucidation, we were able to link this new NRPS gene
cluster to a group of potent anti-MRSA antibiotics, the WAP-
8294A family. Although these compounds have been known
for many years and WAP-8294A2 is currently in clinical stud-
ies, their biosynthetic genes and mechanism have not been
reported.
The core of the WAPS cluster is the two huge NRPS genes
(WAPS1 and WAPS2). A total of 45 domains were identified
from the two genes, representing one of the largest NRPS
systems. The domains make up the 12 modules responsible for
the recognition, activation, thiolation, condensation, and mod-
ification of the 12 amino acids found in WAP-8294A2. The
domain organization of WAPS1 and WAPS2 reveals a “canon-
ical” modular assembly line. The predicted adenylation (A)
domain specificity, based on the “nonribosomal peptide codes”
(46), matches well with the amino acid sequence in the struc-
ture of WAP-8492A2 (Fig. 1 and 2). In addition, the positions
of the epimerase (E) and methytransferase (MT) domains in
WAPS1 and WAPS2 are coincident with the occurrence of the
D-amino acids and N-methyl amino acids in WAP-8492A2. The
12-module organization contains six E domains, matching
the six D-amino acids. There is a perfect “colinearity” between
the 12 modules and the 12 amino acid residues of WAP-
8294A2. WAPS1 starts with a C domain (type CIII), which is a
common feature found in NRPSs for cyclic lipopeptides, such
as surfactin (27), daptomycin (3), and calcium-dependent an-
tibiotic (CDA) of Streptomyces coelicolor A3(2) (9). The N
terminus of surfactin is also acylated with a 3-hydroxy fatty acid
that forms a lactone with the C-terminal carboxyl of the pep-
tide, whereas in daptomycin and CDA the N terminus is acy-
lated with a nonhydroxylated fatty acid and the cyclization
takes place between the C-terminal carboxyl and the hydroxyl
group of an internal amino acid residue (threonine).
While the daptomycin and CDA gene clusters host a dedi-
cated acyl-CoA ligase and an ACP for the activation and in-
corporation of the fatty acyl side chain (3, 9), the surfactin gene
cluster (27) and the WAPS cluster do not contain an ACL. In
the case of surfactin, the B. subtilis genome contains four
putative ACL genes. An in vitro study showed that two of the
ACLs can catalyze the activation and transfer of the 3-hydroxy
fatty acids to the N terminus of the peptide (27). When each of
the four ACL genes was disrupted, the yield of surfactin was
decreased by 38 to 55%. However, even deletion of all four
genes did not abolish surfactin production. Similarly, a disrup-
tion of an ACL gene (accession number JN596953) found in
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the genome of L. enzymogenes OH11 lowered the antibacterial
activity and the yield of WAP-8294A2. The data suggest that
WAP-8492A2 is biosynthetically more close to surfactin than
daptomycin and CDA.
Based on the results, we propose a biosynthetic pathway for
WAP-8294A2 (Fig. 4). The pathway starts with the activation
of the 3-hydroxy fatty acid by the action of a generic ACL. To
incorporate the acyl chain into the peptide, a transferase type
of enzyme is required. This is likely to be accomplished by the
first C domain of WAPS1. This type of so-called type CIII
domain is commonly found in the beginning of the NRPS for
cyclic lipopeptides (3, 4, 27). Such an enzyme can either use the
fatty acyl-S-CoA directly as substrate (21) or use an interme-
diate acyl-S-ACP (Fig. 4) (4). The 7 modules of WAPS1 are
predicted to activate, respectively, L-Ser1, L-Asn2, L-Ser3, Gly4,
L-Phe5, L-Leu6, and L-Orn7. The E domain in the second, fifth,
and seventh modules is expected to epimerize the L-amino acid
to the corresponding D-form. The MT domain in the fifth
module is responsible for adding the methyl group on the
amino nitrogen of the phenylalanine residue. The second
amino acid residue, Asn2, is also hydroxylated at the  position.
This is likely carried out by the 2-ketoglutarate-dependent
dioxygenase (ORF4), which is required for WAP-8294A2 pro-
duction. The timing of this hydroxylation can be prior to or
after the condensation between this residue and the following
residue (Ser3), while the intermediates are WAPS1 bound.
Like WAPS1, WAPS2 also starts with a condensation (C)
domain. This C domain is responsible for transferring the
heptapeptidyl chain on the last PCP domain of WAPS1 to
WAPS2 by catalyzing the condensation between this peptidyl
chain and the eighth residue (Glu8) on the first PCP domain of
WAPS2. The following three modules all contain an E domain,
corresponding to the D-configuration of Asn9, Trp10, and
Orn11. The last module of the 5-module WAPS2 contains an
MT, which is expected to transfer the methyl group onto the
amino nitrogen of the 12th residue (Val12) of WAP-8294A2.
Finally, the fatty acyl-capped dodecapeptidyl chain is trans-
ferred to the serine active site of the thioesterase (TE) domain
located at the end of WAPS2. This TE is predicted to catalyze
the intramolecular macrocyclization by using the 3-hydroxy
group of the fatty acyl chain as the nucleophile to attack the
carbonyl carbon of the peptidyl-O-TE (Fig. 4) (12). This would
release the lipopeptide as a lactone. The TE domain is ex-
pected to have a relax substrate specificity for the length of the
fatty acyl chain, since WAP-8294A analogs differ mainly in this
side chain length. The relaxed substrate specificity may provide
an opportunity to generate new WAP-8294A analogs through
precursor feeding or overexpression of an ACL that activates a
particular type of acyl chains.
A number of cyclic lipopeptides, including surfactin, dap-
tomcyin, and CDA, have been extensively studied (3, 4, 27, 43,
47). So far, daptomycin is the only one that has been incorpo-
rated into the market (Cubicin). In light of the enormous
success of daptomcyin and the clinical trials of WAP-8294A2,
the identification and characterization of the WAP-8492A2
biosynthetic gene cluster will set the foundation for future
genetic engineering to produce new “surfactin-type” anti-
MRSA antibiotics. One particularly attractive point of this
gene cluster is the producer organism, Lysobacter, which is a
ubiquitous soil/water microorganism but has not been well
exploited. Lysobacter is a Gram-negative gliding bacterium
distinct from Streptomyces. The majority of the currently in-use
FIG. 4. Proposed biosynthetic pathway for WAP-8294A2 products from L. enzymogenes.
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or under-study cyclic peptides (including daptomcyin) or
polyketide anti-infectives were isolated from Streptomyces or
other Gram-positive bacteria. Lysobacter is fast-growing, sim-
ple to use and maintain, and readily accessible to genetic tools,
with capacities for posttranslational modifications and avail-
ability of the substrate pool for polyketides and nonribosomal
peptide biosynthesis. Furthermore, Lysobacter is known as a
prolific producer of bioactive compounds, such as cephabacins
(11, 28), HSAF (33, 52), lysobactin (5, 7, 20, 37), and tripro-
peptins (18, 19). So far, none of these pathways has been
genetically manipulated for new antibiotic production. The
availability of the WAP-8294A2 biosynthetic genes, the devel-
opment of the genetic system for L. enzymogenes, and an un-
derstanding of the biosynthetic mechanism will open a new
area of antibiotic research of the Gram-negative producers.
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